PHILADELPHIA, Sept. 15, 2025 -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.
Shareholders of HIMS & HERS may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bergermontague.com or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or by CLICKING HERE.
Berger Montague's investigation is focused on whether Hims & Hers' Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company's partnership with Novo Nordisk, including in connection with Novo Nordisk's announcement in June 2025 that it was terminating its partnership with Hims & Hers on the basis that the Company had engaged in deceptive marketing practices with respect to unapproved compounded versions of semaglutide.
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
Radha Raghavan, Associate
Berger Montague
(332) 271-8908
rraghavan@bergermontague.com
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
